Skip to content

Study · Randomized controlled trial · n = 11 · 2002

11 results

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O

Diabetes1 Feb 2002Cited by 201 (Europe PMC)

PMID11812750 (opens in a new tab)DOI10.2337/diabetes.51.2.424 (opens in a new tab)PepBankPUB-11812750
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, a single bedtime dose of NN2211 (liraglutide) significantly reduced fasting plasma glucose versus placebo.

    In plain wordsIn people with type 2 diabetes, one bedtime dose of liraglutide lowered fasting blood sugar more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose
    Study

    n = 11

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Measurements

    Fasting plasma glucose
    6.9 mmol/l
    NN2211

    Source sentences

    Summary
    plasma glucose was significantly reduced (6.9 +/- 1.0 vs. 8.1 +/- 1.0 mmol/l; P = 0.004)
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, a single bedtime dose of NN2211 (liraglutide) increased the fasting insulin secretion rate versus placebo.

    In plain wordsIn people with type 2 diabetes, one bedtime dose of liraglutide raised fasting insulin release compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseFasting insulin secretion rate
    Study

    n = 11

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Source sentences

    Summary
    ISR was increased (179 +/- 70 vs. 163 +/- 66 pmol/min; P = 0.03)
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, fasting plasma glucagon was unaltered by a single bedtime dose of NN2211 (liraglutide).

    In plain wordsIn people with type 2 diabetes, one bedtime dose of liraglutide did not change fasting glucagon compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting plasma glucagon
    Study

    n = 11

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Source sentences

    Summary
    plasma glucagon was unaltered (19 +/- 4 vs. 20 +/- 4 pg/ml; P = 0.17)
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, the meal-related glucose AUC was markedly reduced by a single bedtime dose of NN2211 (liraglutide) versus placebo.

    In plain wordsIn people with type 2 diabetes, one bedtime dose of liraglutide lowered blood sugar after a meal more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMeal-related glucose AUC
    Study

    n = 11

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Source sentences

    Summary
    Meal-related area under the curve (AUC)(1130-1530 h) for glucose was markedly reduced (30.6 +/- 2.4 vs. 39.9 +/- 7.3 mmol x l(-1) x h(-1); P < 0.001)
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, the meal-related insulin secretion rate AUC was unchanged by a single bedtime dose of NN2211 (liraglutide).

    In plain wordsIn people with type 2 diabetes, total insulin release after a meal did not change with one bedtime dose of liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeMeal-related insulin secretion rate AUC
    Study

    n = 11

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Source sentences

    Summary
    ISR AUC(1130-1530 h) was unchanged (118 +/- 32 vs. 106 +/- 27 nmol; P = 0.13)
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, the meal-related increment in insulin secretion rate was increased by a single bedtime dose of NN2211 (liraglutide).

    In plain wordsIn people with type 2 diabetes, one bedtime dose of liraglutide raised the rise in insulin release after a meal.

    Peptide
    Liraglutide
    Outcome
    IncreaseMeal-related increment in insulin secretion rate
    Study

    n = 11

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Source sentences

    Summary
    but the increment (relative to premeal values) was increased (65 +/- 22 vs. 45 +/- 11 nmol; P = 0.04)
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, the meal-related glucagon AUC was suppressed by a single bedtime dose of NN2211 (liraglutide).

    In plain wordsIn people with type 2 diabetes, one bedtime dose of liraglutide lowered glucagon after a meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMeal-related glucagon AUC
    Study

    n = 11

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Source sentences

    Summary
    Glucagon AUC(1130-1530 h) was suppressed (77 +/- 18 vs. 82 +/- 17 pmol x l(-1) x h(-1); P = 0.04).
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, a single bedtime dose of NN2211 (liraglutide) significantly delayed gastric emptying.

    In plain wordsIn people with type 2 diabetes, one bedtime dose of liraglutide slowed stomach emptying compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseGastric emptying
    Study

    n = 11

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Source sentences

    Summary
    Gastric emptying was significantly delayed as assessed by AUC(1130-1530 h) of 3-ortho-methylglucose (400 +/- 84 vs. 440 +/- 70 mg x l(-1) x h(-1); P = 0.02).
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  9. 09HumanRandomized controlled trialMechanism

    In patients with type 2 diabetes, NN2211 (liraglutide) showed only a tendency toward greater high-frequency regularity of insulin release (0.05 < P < 0.10).

    In plain wordsIn people with type 2 diabetes, liraglutide tended to make insulin release more regular, but the result was not significant.

    Peptide
    Liraglutide
    Outcome
    No significant changeRegularity of insulin release during glucose pulse entrainment
    Study

    n = 11

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Source sentences

    Summary
    During pulse entrainment, there was a tendency to increased high frequency regularity of insulin release as measured by a greater spectral power and autocorrelation coefficient (0.05 < P < 0.10).
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  10. 10HumanRandomized controlled trialPharmacokinetics

    In patients with type 2 diabetes, after a single bedtime dose NN2211 (liraglutide) had a half-life of 10.0 h and a tmax of 12.4 h.

    In plain wordsIn people with type 2 diabetes, liraglutide after one dose had a half-life of about 10 hours and peaked at about 12 hours.

    Peptide
    Liraglutide
    Outcome
    Not applicableHalf-life and time to peak concentration
    Study

    n = 11

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Measurements

    T1/2
    10 h
    NN2211
    Tmax
    12.4 h
    NN2211

    Source sentences

    Summary
    The pharmacokinetic profile of NN2211, as assessed by blood samplings for up to 63 h postdosing, was as follows: T(1/2) = 10.0 +/- 3.5 h and T(max) = 12.4 +/- 1.7 h.
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.
  11. 11HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, two patients experienced gastrointestinal side effects on the day of active NN2211 (liraglutide) treatment.

    In plain wordsIn people with type 2 diabetes, two of 11 patients had stomach or gut side effects on the day of liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    Not applicableGastrointestinal side effects
    Study

    n = 11

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    10 microg/kg single dose · single doseAs given in this study (human).

    Source sentences

    Summary
    Two patients experienced gastrointestinal side effects on the day of active treatment.
    2 context sentences
    Summary · context
    To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 +/- 7 years (mean +/- SD), BMI 28.9 +/- 3.0 kg/m(2), HbA(1c) 6.5 +/- 0.6%, in a double-blind, placebo-controlled, crossover design.
    Summary · context
    A single injection (10 microg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01507311

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 11Sept 1999 to Dec 1999

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 24 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.